Dasatinib and Its Effects on Bone Cell Differentiation
Author Information
Author(s): Id Boufker, Laureance Lagneaux, Mehdi Najar, Martine Piccart, Ghanem Ghanem, Jean-Jacques Body, Fabrice Journé
Primary Institution: Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Hypothesis
Dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Conclusion
Dasatinib promotes osteoblast differentiation and inhibits RANKL expression, suggesting its potential as a treatment for bone loss.
Supporting Evidence
- Dasatinib significantly increased alkaline phosphatase activity and calcium deposition in MSC.
- Dasatinib downregulated RANKL expression, which is crucial for osteoclast differentiation.
- The study identified five key markers of osteoblast differentiation.
- Dasatinib was shown to inhibit Src phosphorylation in MSC.
- Calcium deposition was enhanced in the presence of dasatinib and DAG.
Takeaway
Dasatinib helps bone cells grow and can stop other cells that break down bone from working too much.
Methodology
The study evaluated the effects of dasatinib on MSC differentiation into osteoblasts using various assays over 21 days.
Potential Biases
Potential conflicts of interest due to funding from Bristol Myers Squibb.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
Bone marrow was harvested from 10 healthy volunteer donors with a mean age of 25 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website